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Abstract 
 
Toll like receptors (TLR) are critical mediators of the immune system with their activation 
linked to infection, inflammation and the pathogenesis of immune diseases including 
autoimmunity and cancer. For this reason, over the last two decades, TLR and their 
associated signalling pathways have been targeted therapeutically to enhance innate and 
adaptive immunity. Several TLR ligands, both endogenous and synthetic are at various 
phases of clinical testing, and new ligands are continually emerging. Agonists of TLR7 are 
known immune response modifiers, simultaneously stimulating several cell types, resulting in 
immune cell activation and cytokine and chemokine release. The immune stimulating 
properties of the TLR7 agonist Imiquimod has also been exploited for use in the treatment of 
malignant superficial tumours of the skin. Here, we investigated a novel TLR7 agonist UC-
1V150 and demonstrate it activates both human and mouse myeloid cells in vitro and in vivo, 
to deliver potent FcγR mediated engulfment of opsonised target cells. 
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Introduction 
Toll like receptors (TLR) play a major role in host defence by sensing distinct molecular 
components of bacteria, fungi and viruses. Once engaged they elicit phenotypic and 
functional changes in the many immune cell populations that express these receptors, 
stimulating innate immunity 1, 2. TLR activation also supports the subsequent development of 
adaptive immunity and therefore TLR agonists can be harnessed to enhance vaccinal 
responses 3. Given their ability to provide these potent immune effects, TLR agonists are 
currently being explored in a number of pre-clinical and clinical immunotherapy studies, 
either as vaccine adjuvants or in combination with monoclonal antibodies (mAb) 4. However, 
very few TLR agonists have been approved for clinical use to date with a few notable 
exceptions: the Mycobacterium bovis bacillus calmette-guerin (BCG) and Imiquimod as 
monotherapies, and monophosphoryl lipid A (MPLA) as a vaccine component 5.  
Imiquimod (Aldara®), is a TLR7 agonist which was developed as a topical cream and 
approved by the FDA in 2004 for the treatment of superficial basal cell carcinoma (BCC). 
Although its mechanism of action is not completely understood, it is thought to exert its anti-
tumour effect by inducing apoptosis of the BCC cells 6. In a recent phase 2 study in patients 
with bladder cancer, Imiquimod showed clinical activity, with some complete responses 7. 
Imiquimod has also been examined in combination; decreasing the number of metastases in 
the B16F10 melanoma model in combination with radiotherapy; suggesting that Imiquimod 
could serve as a radiosensitizer in melanoma patients 8. However, topical application of 
Imiquimod can also induce and exacerbate autoimmune skin inflammation akin to  
psoriasis 9-12. In the mouse these effects result from an influx of various immune cells into 
the skin, epidermal hyperplasia and Th-17/IL-23 activation. This has led to Imiquimod-
induced mouse psoriasis being widely used as an animal model in which to study 
autoimmune skin inflammation 13, 14. Although Imiquimod appears to be a viable option for 
the treatment of superficial skin malignancies, there is a pressing need to identify, 
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characterise and develop additional TLR agonists that provide more systemic and potent 
effects. 
We recently examined the potential of a range of TLR agonists for their ability to activate 
innate immune cells, including mouse and human macrophages, in order to improve mAb-
mediated immunotherapy 15. Although Imiquimod demonstrated some activity, it was unable 
to significantly augment mAb-immunotherapy. One possibility was that Imiquimod is not 
sufficiently potent to elicit these responses and so here we examined the potential of an 
alternative TLR7 agonist, 4-[6-amino-8-hydroxy-2-(2-methoxyethoxy)purin-9-
ylmethyl]benzaldehyde (UC-1V150) 16. UC-1V150 is synthesized from 2,6-dechloropurine  
with a free aldehyde group on the benzyl moiety so that it can be coupled to auxiliary 
chemical entities/proteins of interest 16 and has been successfully conjugated to mAbs of 
clinical relevance raising the prospect of cell-targeted TLR activation 17. To date, the 
therapeutic effect of UC-1V150 has only been studied in the context of infectious disease, 
where it was seen to stimulate murine macrophages to produce the proinflammatory 
cytokines IL-6 and IL-12 in vitro and in vivo 16. However, the ability of this reagent to provide 
adjuvant effects to mAb immunotherapy remains to be explored. Here we provide evidence 
that UC-1V150 potently activates macrophages, enhances engulfment of tumour cells in 
vitro, and augments mAb mediated target cell depletion in vivo.   
 
Materials and Methods 
 
Clinical Samples and Ethics 
Ethical approval was obtained by Southampton University Hospitals NHS Trust from 
Southampton and South West Hampshire Research Ethics Committee. Informed consent 
was provided in accordance with the Declaration of Helsinki. CLL samples were from a 
Human Tissue Authority licensed University of Southampton, Cancer Sciences Unit Tissue 
Bank and leukocyte cones were from Southampton General Hospital National Blood Service. 
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Animals 
Mice were bred and maintained in local facilities and experiments approved by the local 
ethical committee under Home Office license PPL30/2964. Experiments conformed to the 
Animal Scientific Procedure Act (UK).   
 
 Synthesis of 4-((6-amino-2-(2-methoxyethoxy)-8-oxo-7,8-dihydro-9H-purin-9-
yl)methyl)benzaldehyde: UC-1V150 
UC-1V150 was synthesized according to previously reported procedure16 and retrieved as 
an off-white solid, and reconstituted in DMSO.  
 
Phagocytosis assay  
PBMC from leukocyte cones were purified by LymphoprepTM (Axis-Shield) density 
centrifugation and cell number  adjusted to a concentration of 1x107 cells/ml in RPMI 1640 
conditioned with 1% Human AB serum, Penicillin, Streptomycin, L-Glutamine and Sodium 
pyruvate (Sigma-Aldrich), 2ml/well plated in a 6 well tissue culture plate and left to incubate 
for two hours at 37oC in 5% CO2. Non-adherent cells were then removed and adherent cells 
incubated for 6 days in the presence of 100ng/ml recombinant human M-CSF (generated in 
house) in RPMI 1640 containing 10% FCS, penicillin, streptomycin, L-glutamine and sodium 
pyruvate. Cells were fed on alternative days 18. Human monocyte derived macrophages 
(hMDM) generated this way were then polarised to M1 or M2 using LPS: 50 ng/ml, 
recombinant human (rh) IFN-γ: 2 ng/ml (Peprotech), or rhIL-4: 10 ng/ml (Peprotech), rhIL-13: 
10 ng/ml (Peprotech), respectively. Alternatively, hMDM were stimulated with Imiquimod 
(Invivogen) or UC-1V150 at 1 μg/ml for 48h. Phagocytosis assays were then performed as 
previously described 18 with human chronic lymphocytic leukaemia (CLL) cells as targets. 
Phagocytic index was calculated by dividing the percentage of phagocytic macrophages 
under the test condition by the percentage of phagocytic macrophages seen in the 
unstimulated condition.  
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Phenotypic analysis of macrophages and calculation of FcγR activatory:inhibitory 
(A:I) ratio  
Human and murine FcγR staining was performed as described previously 19. Fluorescently 
conjugated mAb were obtained from BD Biosciences, AbDSerotec, eBioscience or made in-
house. hMDM were stained with anti-human CD40-Alexafluor (AF)488 (Clone ChiLob7/6), 
CD38-AF488 (Clone AT13/5), both in-house, and CD11b-PE (eBioscience). Murine 
splenocytes were stained with anti-mouse CD11b-PE, Ly6C-PerCpCy5.5, Ly6G-PECy7 
(eBioscience), and F4/80-APC (AbD Serotec). Samples were acquired on a FACS calibur or 
canto II (BD Bioscience) and data analysed with FCS express (DeNovo Software). The FcγR 
activatory:inhibitory (A:I) ratio for hMDM was calculated as: MFI for 
FcγRI*FcγRIIA*FcγRIII/FcγRIIB for hMDM and FcγRI*FcγRIII*FcγRIV/FcγRII for murine 
macrophages) giving a value of x for NT macrophage. The results for each test condition 
were then divided by x so that unstimulated macrophages received a ratio of 1. Using this 
approach allows each FcγR to contribute to the A:I ratio, regardless of the fluorochromes 
with which the detecting antibodies are labelled.  
 
In vivo B cell depletion assays 
Depletion of adoptively transferred hCD20 Tg B cells was performed as described previously 
18. In brief, splenocytes from target (T) hCD20Tg and non-target (NT) wild-type mice were 
labelled with 5 μM and 0.5 μM CFSE (Invitrogen), respectively, mixed (1:1), and i.v injected 
into recipients (5-8 × 106 cells/mouse). UC-1V150 (1-10 μg) was administered after 24 and 
48h, followed by Ritm2a (25 μg) or isotype control. Spleens were harvested 16-20h after 
Ritm2a administration, splenocytes stained with anti-mouse CD19-APC (eBioscience) and 
assessed for T:NT ratio.  
 
Statistical analysis 
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Statistical analysis was performed using GraphPadPrism. To compare differences between 
the experimental groups, student’s t tests were performed with Welch’s correction; a P-value 
<0·05 was considered significant at the 95% confidence interval. Stars denote significance 
as follows: *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. 
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Results and discussion 
Agonists of TLR7 have previously been shown to modulate macrophage activation: The TLR7/8 
agonist R-848 was shown to upregulate the activating FcγR and downregulate the inhibitory 
FcγRIIB 20, whereas the TLR7 agonist Imiquimod has been shown to induce pro-inflammatory 
cytokine release 21. However, its effects on macrophage phenotype, FcγR expression and 
function is not known. To assess this and compare the stimulatory potential of UC-1V150, 
we generated macrophages from human peripheral blood monocytes and measured their 
response to Imiquimod and UC-1V150 versus the archetypal M1/M2 stimuli; LPS/IFN-γ and 
IL-4/-13, by measuring CD40 and CD38 for pro-inflammatory activation and CD11b and DC-
SIGN as markers for alternative activation. UC-1V150, but not Imiquimod, showed an 
inflammatory profile resembling LPS/IFN-γ stimulated macrophages with increases in CD40 
and CD38, decreased CD11b, and no change in DC-SIGN (Fig 1). 
 
In line with the inflammatory phenotypic profile observed (Figure 1), UC-1V150 showed an 
increase in the expression of activating FcγRIIA and FcγRIII with no change in expression of 
inhibitory FcγRIIB (Fig 2A) resulting in an increased A:I ratio (Fig 2B), greater to that 
achieved by LPS/IFN-γ stimulation. We did not observe such profound changes in the FcγR 
profile and A:I ratio with the Imiquimod, indicating UC-1V150 is a more potent compound.  
 
The phenotypic and FcγR changes induced by UC-1V150 were indicative of pro-
inflammatory activation and therefore we assessed if these macrophages also displayed 
augmented functional activity in terms of their ability to phagocytose mAb-opsonised primary 
CLL cells (Fig. 2C) by flow cytometry. We have previously demonstrated, through a variety 
of methods, including fluorescence imaging and confocal microscopy techniques 18, 28, that 
phagocytic activity registered by flow cytometry is an accurate portrayal of macrophage 
engulfment of target cells rather than conjugate formation/rosetting around macrophages. 
Using this methodology Imiquimod treated macrophages from the majority of donors showed 
only a modest increase in the phagocytosis of target CLL cells, but UC-1V150 induced a 
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more robust ~1.5 fold increase in phagocytic index compared to untreated hMDM (Fig 2D), 
raising the possibility of synergistic combination with antibody therapeutics. Whilst data are 
presented for a single dose/concentration, prior reports 24,25 suggest that this concentration is 
significantly above the ED50 for both compounds, and for UC-1V150 relatively selective for 
TLR7 17. These compounds do not show major quantitative differences in potency when 
compared in concentration-response analysis of cellular activation or cytokine induction. 
Furthermore, we initially conducted a dose response (0.1, 1 and 10μg/ml of UC-1V150 in 
hMDM cultures and observed 0.1μg/ml had minimal effect on macrophage activation, whilst 
10μg/ml was toxic to the cells [Data not shown]. 
 
After establishing the ability of UC-1V150 to modulate human macrophages in vitro both 
phenotypically and functionally, we asked whether such changes could be seen in vivo, in 
mice. We first injected mice intraperitoneally with UC-1V150 and investigated the differences 
in FcγR expression and A:I ratio induced on splenic macrophages. Without inducing a 
significant influx of inflammatory myeloid cells into the spleen (Fig 3A), UC-1V150 enhanced 
the levels of FcγRI and -IV on splenic macrophages (Fig 3B), culminating in an almost 4-fold 
increase in A:I ratio (Fig 3C). Using a robust, well established adoptive transfer model 18, we 
then assessed the ability of UC-1V150 to augment the mAb-mediated depletion of 
transferred hCD20 Tg B cells. mAb-mediated depletion of hCD20 Tg B cells was also 
significantly enhanced by UC-1V150, both in the spleen (Fig 3D and E) and blood of 
recipient mice (Fig 3F).  
 
Here we provide evidence for the ability of UC-1V150, a relatively new class of TLR7 agonist 
that has not been investigated in the context of mAb therapy and macrophage modulation, to 
augment mAb activity both in vitro and in vivo. Clearly, this has two important implications. 
First, repolarisation of macrophages to an inflammatory profile is a keenly sought goal for 
immunotherapy and the identification of cellular pathways and candidate drugs capable of 
reversing immune suppression in vivo, leading to macrophage polarisation, will allow 
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effective manipulation of these immune effectors in disease settings. This is important in the 
context of macrophages, as they can express all FcγR and have great potential to destroy 
tumours through FcγR-mediated phagocytosis 18. Second, we provide evidence that this 
process is mediated by FcγR changes such that the A:I ratio is tipped in favour of optimal 
mAb therapy. FcγR play a critical role in regulating immune homeostasis and their 
expression must be carefully modulated such that the FcγR A:I ratio is appropriate, 
preventing unsolicited immune effects whilst permitting beneficial proinflammatory responses 
to ensue 22. No overarching role has been ascribed to a single FcγR in mediating these 
effector activities, but it has previously been reported that high FcγRIIB expression may 
explain resistance to the anti-CD20 mAb rituximab; and that the composite function of the A:I 
ratio mirrors the efficacy of the TLR reagent in providing adjuvant effects to mAb 
immunotherapy 23. So-called “Danger signals” provided by TLR activation enable effective 
FcγR A:I ratio skewing, but their efficacy in vivo is limited. For instance, the TLR1/2 agonist 
Pam3CSK4 robustly induced favourable FcγR A:I changes, inflammation and phagocytosis 
of target cells in vitro, but failed to achieve this in vivo 15. Therefore, drugs such as UC-
1V150 that promote appropriate FcγR expression profiles in vivo, with the potential for 
murine to human translation raise the possibility of providing synergistic treatments with 
existing antibody therapeutics. However, TLR7 activation on B cells may influence selection, 
proliferation and diversification of the repertoire of B cells in the germinal centre, impeding 
the B cell tolerance checkpoints 26. 27. Therefore, a better understanding of the interaction 
between the B-cell receptor (BCR) and TLR7, as well as careful modulation of their 
responses, is critical when identifying potential therapeutic reagents targeting TLR7 as its 
hyperactivation may lead to autoantibody production by BCR activated cells potentially 
resulting in autoimmunity.  
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Figure legend 
Figure 1: TLR-7 agonist UC-1V150 skews human macrophage towards LPS/IFN-γ like 
profile: hMDM were stimulated with LPS/IFN-γ (L/γ), IL-4/-13 (4/13) or TLR7 agonists 
Imiquimod (Imi) or UC-1V150 for 48 hours and were assessed for changes in expression of 
cell surface markers CD40, CD38, CD11b and DC-SIGN by flow cytometry; (A) 
representative histograms. Open black histogram: Iso ctrl for non-treated (NT) macrophage, 
Filled black histogram: Expression of surface markers on NT macrophage, Open grey 
histogram: Iso ctrl for TLR7a treated macrophage, Filled grey histogram: Expression of 
surface marker in TLR7a treated macrophage. (B) MFI for each surface marker shown, data 
combined for 3-4 different donors, error bars ±SEM (* compared to NT samples).  
Figure 2: FcγR expression and antibody dependent phagocytosis of tumour cells 
following stimulation of hMDM with UC-1V150. A. hMDM stimulated with LPS/IFN-γ (L/γ) 
IL-4/-13 (4/13), Imiquimod (Imi) or UC-1V150 for 48 hours were assessed for changes in 
expression of FcγR by flow cytometry; representative histograms shown. Open black 
histogram: Isotype control for non-treated (NT) macrophage, Filled black histogram: 
Expression of FcγR in NT macrophage, Open grey histogram: Isotype control for TLRa 
treated macrophage, Filled grey histogram: Expression of FcγR in TLRa treated 
macrophage. B. Changes in FcγR A:I ratio in relation to NT macrophages expressed as 1, 
data combined for 3-4 different donors, error bars ±SEM, C. CFSE labelled target CLL cells 
opsonised with anti-CD20 antibody rituximab were co-cultured with hMDM previously 
stimulated with LPS/IFN-γ, IL-4/-13, or TLR7a and then assessed for phagocytosis. 
CFSE+CD16+ events indicate macrophages that have engulfed target cells.  D. Phagocytic 
index calculated in relation to NT macrophages expressed as 1. Each data point represents 
an individual donor (* compared to NT samples). 
Figure 3: Effect of UC-1V150 on mAb-mediated target B cell depletion in vivo. A-C. WT 
C57BL/6 mice were primed with UC-1V150 and the myeloid cells assessed in the spleen 48 
hours later by flow cytometry. A) Cellular content: F4/80+ cells correspond to macrophages 
while Ly6C+ and Ly6G+ cells within the CD11b+ gate are monocytes and neutrophils, 
respectively. Upper dot plots: Naïve mice; lower dot plots: UC-1V150 treated mice. B. 
Expression of FcγR on splenic macrophages: open black histogram: Isotype control from 
naïve mice, filled black histogram: expression of FcγR from naïve mice; open grey 
histogram: isotype control from UC-1V150 treated mice, filled grey histogram: expression of 
FcγR from UC-1V150 treated mice. C. A:I ratio on splenic macrophages calculated from B. 
D-E. WT C57BL/6 were primed with UC-1V150 after transfer of target (T) hCD20Tg B cells 
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and non-Tg non-target (NT) B cells; and treated with Ritm2a. Mice were then assessed for 
target hCD20Tg B cell depletion in the spleen (D, E) and blood (F) and expressed as a T:NT 
ratio. Results shown are pooled from 2 independent experiments (1 experiment for blood) 
with n=3/group in each experiment).  
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